Introduction: Phosphatidylinositol 3-kinase (PI3K) is a therapeutic target for patients (pts) with indolent non-Hodgkin's lymphoma (iNHL). Copanlisib is a pan-Class I PI3K inhibitor with predominant activity against PI3K-α and PI3K-δ isoforms. In contrast to oral PI3K inhibitors that are dosed continuously, intermittent IV administration of copanlisib has demonstrated a different safety profile. We report results here from a pooled safety analysis. Methods: Safety data from 4 studies (NCT00962611, NCT01660451 parts A and B, and NCT02155582) including iNHL pts were pooled for analysis. All pts had received IV copanlisib on days 1, 8, and 15 of a 28-day cycle at either 0.8 mg/kg or an equivalent fixed dose of 60 mg. Treatment emergent adverse events (TEAE) were reported using MedDRA terms and worst NCI CTCAE grading. Results: A total of 168 pts with iNHL were available for safety analysis, including follicular (75%) and marginal zone lymphoma (15%) pts. Median prior lines of therapy was 3 (range 1-10); including rituximab (n = 168) and alkylating agents (n = 167). The mean duration of treatment was 30.2 weeks (±30.4) and mean number of cycles 7.5 (±7.6). The most commonTEAEs (occurring in ≥20% of the pts) were transient hyperglycemia (51%), diarrhea (36%), transient hypertension (35%), fatigue (29%), nausea (26%), neutropenia (25%), and pyrexia (24%). The most common grade 3 TEAEs (≥5%) were hyperglycemia (32%), hypertension (27%), neutropenia (8%), and pneumonia (8%); hyperglycemia and hypertension were transient and largely asymptomatic. Grade 4 TEAEs (≥5%) were neutropenia (12%) and hyperglycemia (6%). SeriousTEAEs (≥2%) were pneumonia (10%), pyrexia, hyperglycemia and pneumonitis (5% each), neutropenia, diarrhea and lung infection (2% each). There were six grade 5 TEAEs, with 3 reported as drug-related: lung infection, respiratory failure, and embolism. Infections (≥5%) included upper respiratory (14%), pneumonia (11%), bronchitis (9%), urinary (7%), oral herpes (6%), and rhinitis (5.4%). Opportunistic fungal infections occurred in 3 pts; two Pneumocystis jiroveci pneumonia and one bronchopulmonary aspergillosis. GI toxicity included grade 3 diarrhea (5%) and one case of colitis (grade 4) was reported. Suspected non-infectious pneumonitis was reported in 9% (3% grade 3 and no grade 4/5). Treatment discontinuations due to TEAEs (24%) included pneumonitis (2%), neutropenia, thrombocytopenia, fatigue, pneumonia, platelet count decreased, and hyperglycemia (1.8% each). Conclusions: Integrated safety analysis demonstrates that copanlisib had a tolerable and manageable safety profile with a low rate of severe gastrointestinal toxicities, hepatotoxicities, pneumonitis, and opportunistic infections. The most common grade 3 AEs were transient hyperglycemia and transient hypertension, both of which were predictable and manageable and did not lead to significant discontinuation.
Mendeley helps you to discover research relevant for your work.
CITATION STYLE
Zinzani, P., Dreyling, M., Patnaik, A., Morschhauser, F., Benson, A., Genvresse, I., … Childs, B. H. (2017). INTEGRATED SAFETY DATA WITH COPANLISIB MONOTHERAPY FROM PHASE I AND II TRIALS IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN’S LYMPHOMA. Hematological Oncology, 35(S2), 269–269. https://doi.org/10.1002/hon.2438_141